Pharmaceutical Product Monograph: Diclofenac Sodium Injection (25 mg/mL or 75 mg/3 mL)
In the pharmaceutical industry, Diclofenac Sodium is a potent Non-Steroidal Anti-Inflammatory Drug (NSAID) belonging to the phenylacetic acid group. As a pharmacist and manufacturer, I view this molecule as a “COX-Inhibition Workhorse”—it is technically designed to provide rapid, high-concentration analgesia by shutting down the chemical messengers of pain and inflammation at the source.
At your WHO-GMP facility in Mumbai, Diclofenac 75 mg/3 mL is a foundational SKU for Orthopedic, Rheumatology, and Post-Operative portfolios. The injectable form is preferred over tablets when an immediate onset of action is required or when the patient cannot take oral medication.
Therapeutic Profile: Primary Indications
Diclofenac Sodium injection is indicated for the short-term treatment of acute, severe pain and inflammation.
| Indication | Clinical Context | Technical Rationale |
| Renal Colic | Kidney Stones | Gold Standard: Extremely effective at reducing the smooth muscle spasms and intense pain associated with stones. |
| Post-Operative Pain | Surgery Recovery | Used as an opioid-sparing agent to manage pain following orthopedic or dental surgery. |
| Acute Osteoarthritis | Joint Flares | Provides rapid relief from the swelling and mechanical pain of “bone-on-bone” inflammation. |
| Rheumatoid Arthritis | Autoimmune Flares | Manages acute systemic inflammatory episodes in the joints. |
| Acute Gout | Uric Acid Crisis | Reduces the extreme inflammation and “heat” associated with gout attacks. |
| Severe Migraine | Neurology | Used in ER settings for the rapid termination of a status migrainosus attack. |
Mechanism: Dual COX Inhibition
Diclofenac works by sabotaging the production of Prostaglandins, the primary chemicals that sensitize pain receptors:
Enzyme Inhibition: It inhibits both Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2).
Prostaglandin Blockade: By blocking these enzymes, it prevents the conversion of arachidonic acid into prostaglandins ($PGE_2$).
Threshold Elevation: With fewer prostaglandins present, the threshold for pain at the nerve endings is technically raised, meaning the patient “feels” significantly less pain.
Anti-pyretic Effect: It also acts on the hypothalamus to reduce fever.
The Pharmacist’s “Technical Warning”
The “Deep IM” Rule: As a pharmacist, I must emphasize that Diclofenac is highly irritating to tissues. It must be given by Deep Intramuscular (IM) injection into the upper outer quadrant of the gluteal muscle. Shallow injections can cause sterile abscesses or tissue necrosis.
The “Bolus” Contraindication: Standard Diclofenac Sodium (75 mg/3 mL) is generally not for IV bolus. If used intravenously, it must be diluted in at least 100 mL of Saline or Glucose and infused over 30–120 minutes.
Asthma Sensitivity: Technically, about 10% of asthmatics may have “Aspirin-Sensitive Asthma.” Diclofenac can trigger a severe bronchospasm in these patients.
Renal Risk: It can reduce blood flow to the kidneys. Use with extreme caution in dehydrated patients or those with pre-existing renal impairment.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai:
The “Solubility” USP: Diclofenac Sodium is notoriously difficult to keep in solution. On your digital marketplace, highlight your use of Co-solvents (like Propylene Glycol) and pH stabilizers. This prevents the “crystal precipitation” often seen in low-quality generics when stored in cooler climates.
The “Aqua” Formulation Advantage: If your facility produces the newer Diclofenac Sodium 75 mg/1 mL (Aqueous), market this as your “Premium SKU.” It allows for a smaller injection volume, significantly reducing patient pain at the injection site compared to the traditional 3 mL ampoule.
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Diclofenac 75 mg/3 mL ampoules to support your registration in international B2B tenders for emergency medicine and orthopedics.